Generation Bio Overview
Latest ROE for Generation Bio: -123.87% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-123.87%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Generation Bio (GBIO) currently reports a ROE of -123.87%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Generation Bio's ROE history and peer comparisons.
Generation Bio's ROE of -123.87% is lower than the Healthcare sector average of 22.01%. That is roughly 662.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Generation Bio's current -123.87% should be judged against Healthcare norms (sector average: 22.01%) and against GBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -123.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Generation Bio, and consider following GBIO for alerts when major investors trade the stock.
Generation Bio is classified in the Healthcare sector. On ROE, it currently shows -123.87% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GBIO with unrelated industries.
